BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · IEX Real-Time Price · USD
6.55
-0.12 (-1.80%)
At close: Jul 2, 2024, 4:00 PM
6.50
-0.05 (-0.76%)
After-hours: Jul 2, 2024, 7:24 PM EDT
BioCryst Pharmaceuticals Employees
BioCryst Pharmaceuticals had 536 employees as of December 31, 2023. The number of employees increased by 5 or 0.94% compared to the previous year.
Employees
536
Change (1Y)
5
Growth (1Y)
0.94%
Revenue / Employee
$663,050
Profits / Employee
-$389,151
Market Cap
1.35B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 536 | 5 | 0.94% |
Dec 31, 2022 | 531 | 173 | 48.32% |
Dec 31, 2021 | 358 | 112 | 45.53% |
Dec 31, 2020 | 246 | 106 | 75.71% |
Dec 31, 2019 | 140 | 40 | 40.00% |
Dec 31, 2018 | 100 | 15 | 17.65% |
Dec 31, 2017 | 85 | 20 | 30.77% |
Dec 31, 2016 | 65 | -5 | -7.14% |
Dec 31, 2015 | 70 | 20 | 40.00% |
Dec 31, 2014 | 50 | 10 | 25.00% |
Dec 31, 2013 | 40 | 0 | - |
Dec 31, 2012 | 40 | -35 | -46.67% |
Dec 31, 2011 | 75 | -1 | -1.32% |
Dec 31, 2010 | 76 | -3 | -3.80% |
Dec 31, 2009 | 79 | -1 | -1.25% |
Dec 31, 2008 | 80 | -26 | -24.53% |
Dec 31, 2007 | 106 | 21 | 24.71% |
Dec 31, 2006 | 85 | 33 | 63.46% |
Dec 31, 2005 | 52 | 2 | 4.00% |
Dec 31, 2004 | 50 | 4 | 8.70% |
Dec 31, 2003 | 46 | 2 | 4.55% |
Dec 31, 2002 | 44 | -33 | -42.86% |
Dec 31, 2001 | 77 | 11 | 16.67% |
Dec 31, 2000 | 66 | 6 | 10.00% |
Dec 31, 1999 | 60 | 4 | 7.14% |
Dec 31, 1998 | 56 | 1 | 1.82% |
Dec 31, 1997 | 55 | 2 | 3.77% |
Dec 31, 1996 | 53 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Brookdale Senior Living | 36,000 |
Omnicell | 3,650 |
Phreesia | 1,438 |
Pacira BioSciences | 712 |
ANI Pharmaceuticals | 642 |
Vir Biotechnology | 587 |
Sana Biotechnology | 328 |
Kiniksa Pharmaceuticals | 297 |
BCRX News
- 18 hours ago - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment - GlobeNewsWire
- 7 weeks ago - BioCryst to Present New Data at 2024 Meeting of the European Academy of Allergy and Clinical Immunology - GlobeNewsWire
- 7 weeks ago - ORLADEYO® (berotralstat) Approved in Mexico - GlobeNewsWire
- 7 weeks ago - BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat) - GlobeNewsWire
- 2 months ago - BioCryst to Present at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - BioCryst Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - BioCryst to Report First Quarter 2024 Financial Results on May 6 - GlobeNewsWire